Education
About Us
Working with TipRanks
Follow Us
BriaCell Therapeutics Corp (TSE:BCT)
TSX:BCT
RESEARCH TOOLSreports
Total Valuation
BriaCell Therapeutics has a market cap or net worth of C$19.13M. The enterprise value is -C$7.22M.
Market CapC$19.13M
Enterprise Value-C$7.22M
Share Statistics
BriaCell Therapeutics has 17,551,092 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding17,551,092
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BriaCell Therapeutics’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is 2.90%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)2.90%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee0.00
Profits Per Employee-308.22K
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio0.44
Price to Fair Value-5.15
Price to FCF-0.41
Price to Operating Cash Flow-0.23
PEG Ratio<0.01
Income Statement
In the last 12 months, BriaCell Therapeutics had revenue of 0.00 and earned -6.62K in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit-114.04K
Operating Income-46.02K
Pretax Income-6.81K
Net Income-6.62K
EBITDA-45.91K
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -24.07M and capital expenditures 0.00, giving a free cash flow of -24.07M billion.
Operating Cash Flow-24.07M
Free Cash Flow-24.07M
Free Cash Flow per Share-1.37
Dividends & Yields
BriaCell Therapeutics pays an annual dividend of C$0.09, resulting in a dividend yield of ―
Dividend Per ShareC$0.09
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.43
52-Week Price Change-92.19%
50-Day Moving Average3.98
200-Day Moving Average9.10
Relative Strength Index (RSI)13.67
Average Volume (3m)35.02K
Important Dates
BriaCell Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend DateSep 05, 2023
Financial Position
BriaCell Therapeutics as a current ratio of 0.49, with Debt / Equity ratio of 0.00%
Current Ratio0.49
Quick Ratio0.49
Debt to Market Cap0.00
Net Debt to EBITDA18.78
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BriaCell Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BriaCell Therapeutics EV to EBITDA ratio is -248.59, with an EV/FCF ratio of -0.46.
EV to Sales0.00
EV to EBITDA-248.59
EV to Free Cash Flow-0.46
EV to Operating Cash Flow-0.47
Balance Sheet
BriaCell Therapeutics has C$12.46M in cash and marketable securities with $0.00 in debt, giving a net cash position of -C$12.46M billion.
Cash & Marketable SecuritiesC$12.46M
Total Debt$0.00
Net Cash-C$12.46M
Net Cash Per Share-C$0.71
Tangible Book Value Per Share-C$2.63
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for BriaCell Therapeutics is C$43.94, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$43.94
Price Target Upside3931.19% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast56.78%